Sprint PNS Now Covered by Aetna — What It Means for Chronic Pain Patients

In March 2026, Aetna updated its clinical policy to cover Sprint Peripheral Nerve Stimulation (PNS) — a temporary, implant-free nerve stimulation therapy — for specific chronic pain conditions. For patients who have tried physical therapy, medications, and injections without lasting relief, this is a meaningful development.

Dr. Knopp has been performing Sprint PNS at Hartford HealthCare's Pain Treatment Center, and the new Aetna coverage significantly expands who can access it. Here's what you need to know.

What Is Sprint PNS?

Sprint Peripheral Nerve Stimulation is a short-term (60-day) neuromodulation therapy. A thin wire electrode is placed near the affected peripheral nerve under ultrasound guidance — no surgery, no permanent implant. A small external pulse generator worn on the body delivers mild electrical signals that interrupt pain transmission.

After 60 days, the electrode is removed in a brief office procedure. No hardware remains in the body.

This is categorically different from spinal cord stimulation (SCS), which involves a permanent implant near the spinal cord. Sprint PNS targets peripheral nerves — the nerves outside the spine — making it appropriate for localized pain that hasn't responded to conservative treatment.

What the Evidence Shows

The evidence base for Sprint PNS is substantial. A multicenter study published in Pain Medicine evaluated 6,160 patients treated with peripheral nerve stimulation for shoulder, knee, lower back, and foot/ankle pain. Among those with chronic pain who had already tried and failed multiple treatments:

• 71% achieved ≥50% pain reduction — the standard threshold for clinical success
• 54% achieved ≥80% pain reduction — near-complete relief
• Mean pain scores dropped from 6.9/10 to 2.7/10 at 60-day follow-up
• Functional improvement was maintained at 3-month follow-up in the majority of responders

These numbers matter because the patient population studied wasn't a cherry-picked trial group — it included people with complex, treatment-resistant pain who had previously tried injections, physical therapy, and medications.

What Conditions Qualify Under the New Aetna Policy?

Aetna's March 2026 policy update covers Sprint PNS for:

• Chronic shoulder pain (including rotator cuff-related pain and post-surgical shoulder pain)
• Chronic knee pain (including post-arthroplasty pain and osteoarthritic knee pain)
• Chronic low back pain with a peripheral nerve component
• Foot and ankle pain that has failed conservative management

General criteria include: pain duration of at least 3 months, documented failure of conservative treatments (physical therapy, NSAIDs, at least one injection), and a positive response to diagnostic nerve block.

The policy does not cover Sprint PNS for diffuse pain syndromes, fibromyalgia, or central sensitization conditions — it's designed for anatomically specific, peripheral nerve-mediated pain.

How Dr. Knopp Determines Who Is a Candidate

Before recommending Sprint PNS, Dr. Knopp evaluates several factors:

• Pain localization — Is the pain anatomically specific enough to target a single peripheral nerve? A patient with diffuse back pain from a multi-level disc problem may not be an ideal candidate. A patient with well-localized shoulder pain from a suprascapular nerve distribution often is.
• Treatment history — Sprint PNS is not a first-line treatment. At least 3-6 months of documented conservative care is standard, including physical therapy and at least one image-guided injection.
• Diagnostic nerve block response — In most cases, Dr. Knopp will perform a diagnostic block of the target nerve first. A ≥50% temporary reduction in pain from the block is a strong predictor of Sprint PNS success.
• Functional goals — The conversation focuses on what the patient wants to be able to do — return to work, sleep through the night, resume activity — not just a target pain score.

What the 60-Day Treatment Looks Like

The procedure is performed at Hartford HealthCare's Pain Treatment Center in West Hartford. Here's the general sequence:

1. Placement (Day 1): Under ultrasound and/or fluoroscopic guidance, a thin electrode wire is placed near the target nerve through a small introducer needle. The procedure takes 20-45 minutes. Most patients go home the same day.
2. Stimulation (Days 1–60): A small external pulse generator (worn on the body, roughly the size of a credit card) is connected to the electrode lead. Parameters are programmed and adjusted at follow-up visits. Most patients feel a mild buzzing or tingling rather than pain.
3. Removal (Day 60): The electrode is removed in a brief office procedure. No incision required — the wire is simply extracted.

Patients continue normal activity during the treatment period with minor restrictions (no submersion in water, no high-impact activity at the insertion site).

How Sprint PNS Differs from Permanent Spinal Cord Stimulation

This is one of the most common questions Dr. Knopp hears. The short answer: Sprint PNS is a diagnostic and therapeutic tool. SCS is a long-term commitment.

Sprint PNS is often used as a bridge or trial before deciding on a permanent implant. If 60 days of peripheral nerve stimulation provides significant relief, it supports the case that neuromodulation is the right pathway — and helps guide the decision about whether a permanent device makes sense.

It also serves as a standalone treatment. Many patients achieve lasting relief after the 60-day course without needing anything further. The mechanism is thought to involve both direct pain signal interruption and longer-term neuroplastic changes — the nerve "relearns" normal signaling after weeks of modulated input.

How to Find Out If You Qualify

The first step is an evaluation at Dr. Knopp's West Hartford office. During that visit, he'll review your imaging, treatment history, and do a hands-on exam to determine whether Sprint PNS is appropriate — and whether the initial step should be a diagnostic nerve block first.

If you have Aetna insurance and meet the coverage criteria, authorization can typically be obtained before the placement procedure. Dr. Knopp's team coordinates pre-authorization through Hartford HealthCare.